SCHEMBL4468880

SCHEMBL4468880

COC(=O)c1ccc(-c2ccc(OC)cn2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.66
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
MAPT P10636 7/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TP53 P04637 1/20 0.50
CHEK1 O14757 1/20 0.49
PTGER4 P35408 1/20 0.48
THRB P10828 2/20 0.48
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
LMNA P02545 1/20 0.48
ALPL P05186 1/20 0.48
ALDH1A1 P00352 1/20 0.48
DGAT1 O75907 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714830 0.91 RXFP1 (0.75) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL29598250 0.87 MAPK1 (0.61) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL4462126 0.86 RXFP1 (0.68) RXFP1CA1CA2SMN1; SMN2KDM4E
SCHEMBL14872145 0.84 CA1 (0.70) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL12924080 0.84 GABRG2 (0.53) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL4469903 0.83 TDP1 (0.59) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL2345470 0.83 RXFP1 (0.55) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL18818444 0.83 CA1 (0.59) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL31145166 0.83 TDP1 (0.59) RXFP1CA1CA2MAPTSMN1; SMN2
SCHEMBL1179665 0.81 CYP11B1 (0.66) RXFP1CA1CA2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504412-B2 Imidazopyridine derivatives BANYU PHARMACEUTICALS, CO., LTD. (JP) 2009-03-17 US disclosed
US-20080200494-A1 Imidazopyridine Derivatives MSD K.K. (JP) 2008-08-21 US disclosed
EP-1657242-A1 IMIDAZOPYRIDINE DERIVATIVES Banyu Pharmaceutical Co., Ltd. (JP) 2006-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200494-A1 Imidazopyridine Derivatives MC1R, MC3R, MC5R RXFP1 175/4885CA1 4838/4885CA2 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.